Short Interest in Amedisys, Inc. (NASDAQ:AMED) Drops By 18.5%

Amedisys, Inc. (NASDAQ:AMEDGet Free Report) was the recipient of a large decline in short interest during the month of May. As of May 15th, there was short interest totalling 2,020,000 shares, a decline of 18.5% from the April 30th total of 2,480,000 shares. Approximately 6.3% of the shares of the company are short sold. Based on an average daily trading volume, of 363,800 shares, the short-interest ratio is presently 5.6 days.

Amedisys Stock Up 0.1%

Shares of NASDAQ:AMED opened at $94.57 on Thursday. Amedisys has a 52-week low of $82.15 and a 52-week high of $98.95. The firm has a fifty day moving average of $93.59 and a 200 day moving average of $91.66. The firm has a market capitalization of $3.10 billion, a PE ratio of 37.53, a price-to-earnings-growth ratio of 1.78 and a beta of 0.96. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19.

Amedisys (NASDAQ:AMEDGet Free Report) last announced its earnings results on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.13 by $0.12. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The company had revenue of $594.78 million during the quarter, compared to analyst estimates of $597.43 million. During the same period in the previous year, the business earned $1.03 earnings per share. The firm’s quarterly revenue was up 4.1% compared to the same quarter last year. As a group, research analysts anticipate that Amedisys will post 4.4 EPS for the current fiscal year.

Wall Street Analyst Weigh In

AMED has been the topic of a number of research reports. Wall Street Zen cut shares of Amedisys from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 24th. Stephens reissued an “equal weight” rating and set a $101.00 target price on shares of Amedisys in a report on Tuesday, March 4th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $100.00 price target on shares of Amedisys in a research report on Wednesday, April 16th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $100.75.

Get Our Latest Research Report on Amedisys

Institutional Trading of Amedisys

Several institutional investors have recently added to or reduced their stakes in AMED. Hexagon Capital Partners LLC boosted its position in Amedisys by 108.1% during the first quarter. Hexagon Capital Partners LLC now owns 310 shares of the health services provider’s stock valued at $29,000 after buying an additional 161 shares during the period. MassMutual Private Wealth & Trust FSB boosted its position in Amedisys by 56.1% during the first quarter. MassMutual Private Wealth & Trust FSB now owns 334 shares of the health services provider’s stock valued at $31,000 after buying an additional 120 shares during the period. Fifth Third Bancorp boosted its position in Amedisys by 68.1% during the first quarter. Fifth Third Bancorp now owns 348 shares of the health services provider’s stock valued at $32,000 after buying an additional 141 shares during the period. Blue Trust Inc. boosted its position in Amedisys by 55.1% during the fourth quarter. Blue Trust Inc. now owns 349 shares of the health services provider’s stock valued at $34,000 after buying an additional 124 shares during the period. Finally, UMB Bank n.a. boosted its position in Amedisys by 100.0% during the first quarter. UMB Bank n.a. now owns 386 shares of the health services provider’s stock valued at $36,000 after buying an additional 193 shares during the period. 94.36% of the stock is currently owned by hedge funds and other institutional investors.

About Amedisys

(Get Free Report)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Recommended Stories

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.